




RealRate

PHARMACEUTICAL 2021

Lexicon Pharmaceuticals INC
Rank 136 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lexicon Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexicon Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Lexicon Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 319%, being 63% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	157,719
Cost of Goods Sold	1,929
Intangible Assets	44,543
Liabilities, Current	46,806
Liabilities, Non-Current	611
Other Assets	1,231
Other Compr. Net Income	-90
Other Expenses	16,144
Other Liabilities	0
Other Net Income	136,355
Other Revenues	23,995
Property and Equipment	295
Research and Development	153,621
Selling, General and Administrative Expense	47,230

Output Variable	Value in 1000 USD
Assets	203,788
Liabilities	47,417
Expenses	218,924
Revenues	23,995
Stockholders Equity	156,371
Net Income	-58,574
Comprehensive Net Income	-58,619
BaseVar	315,284
ECR before LimitedLiability	225%
Economic Capital Ratio	319%